中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (4): 276-278.doi: 10.12144/zgmfskin202504276

• 临床研究 • 上一篇    下一篇

古塞奇尤单抗治疗银屑病合并艾滋病、丙肝一例

胡宏香,高靖雅,周兴丽,李薇   

  1. 四川大学华西医院皮肤病与性病科，罕见病中心，四川成都，610041
  • 出版日期:2025-04-15 发布日期:2025-04-08

Guselkumab for the treatment of psoriasis combined with AIDS and hepatitis C: a case report

HU Hongxiang, GAO Jingya, ZHOU Xingli, LI Wei   

  1. Department of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu 610041, China
  • Online:2025-04-15 Published:2025-04-08

PDF (PC)

17

摘要： 患者，男，41岁。斑块状银屑病合并艾滋病9年。患者先后接受乌司奴单抗、司库奇尤单抗治疗，效果不佳。2019年改用古塞奇尤单抗治疗，2023年患者确诊丙肝，加用索磷布韦维帕他韦治疗后，肝功能恢复正常。古塞奇尤单抗治疗4年余，患者皮损完全消退后轻度反复，PASI、BSA、DLQI评分显著改善。实验室检查显示CD4+ T细胞计数由405个/μL增至702个/μL，HIV RNA阴性，未见明显不良反应。本病例提示古塞奇尤单抗联合高效抗逆转录病毒治疗（HAART）对银屑病合并艾滋病、丙肝患者安全有效，但需进一步临床试验验证其长期疗效和安全性。

关键词: 斑块状银屑病, 古塞奇尤单抗, 艾滋病

Abstract: A 41-year-old male presented with plaque psoriasis complicated by HIV/AIDS for 9 years. The patient received ulinumab and secuchiumab successively, and the effect was poor. The patient has been treated with guselkumab since 2019, and was diagnosed with hepatitis C in 2023, and liver function returned to normal after the treatment with sofosbuvir vipatavir. The patient was followed up for 4 years and the skin lesions completely subsided after mild recurrence, PASI, BSA, DLQI scores significantly improved. Laboratory tests showed that CD4+ T cell count increased from 405 cells /μL to 702 cells /μL, HIV RNA negative, and no significant adverse effects were observed. This case suggests that goucegiumab combined with highly active antiretroviral therapy (HAART) is safe and effective in patients with psoriasis complicated with HIV and hepatitis C, but further clinical trials are needed to verify its long-term efficacy and safety.

Key words: plaque psoriasis, guselkumab, AIDS